Geulah Livshits
Stock Analyst at Chardan Capital
(2.08)
# 2,858
Out of 4,876 analysts
201
Total ratings
34%
Success rate
-4.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 | $46.71 | +75.55% | 14 | Jun 26, 2025 | |
| PASG Passage Bio | Maintains: Buy | $6 | $0.35 | +1,621.17% | 5 | Jun 24, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 | $3.63 | +258.13% | 12 | Jun 18, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 | $2.15 | +459.44% | 9 | Jun 12, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $7 → $9 | $2.47 | +265.11% | 13 | May 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $46 → $17 | $2.60 | +555.11% | 18 | May 28, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $16 → $12 | $2.58 | +365.12% | 5 | May 19, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $16 → $15 | $4.78 | +213.81% | 7 | May 19, 2025 | |
| IPSC Century Therapeutics | Maintains: Buy | $7 → $6 | $0.56 | +971.43% | 6 | May 16, 2025 | |
| MGX Metagenomi | Maintains: Buy | $13 → $12 | $1.58 | +659.49% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $20 | $4.11 | +387.21% | 9 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $4.00 | +525.00% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $25 | $1.73 | +1,345.09% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 | $9.77 | +596.01% | 14 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $0.65 | +1,278.25% | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $219 | $139.77 | +56.69% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $22.14 | +125.89% | 1 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.18 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.25 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $6.71 | +511.48% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $5.55 | +350.45% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.71 | +601.75% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $27.33 | +661.07% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.43 | +1,018.88% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.99 | +901.11% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $2.94 | +36.05% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $2.47 | +1,114.57% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.86 | +103.27% | 1 | Oct 27, 2020 |
CRISPR Therapeutics AG
Jun 26, 2025
Maintains: Buy
Price Target: $82
Current: $46.71
Upside: +75.55%
Passage Bio
Jun 24, 2025
Maintains: Buy
Price Target: $6
Current: $0.35
Upside: +1,621.17%
Immuneering
Jun 18, 2025
Maintains: Buy
Price Target: $13
Current: $3.63
Upside: +258.13%
Senti Biosciences
Jun 12, 2025
Maintains: Buy
Price Target: $12
Current: $2.15
Upside: +459.44%
Taysha Gene Therapies
May 29, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $2.47
Upside: +265.11%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Buy
Price Target: $46 → $17
Current: $2.60
Upside: +555.11%
Prime Medicine
May 19, 2025
Maintains: Buy
Price Target: $16 → $12
Current: $2.58
Upside: +365.12%
Solid Biosciences
May 19, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $4.78
Upside: +213.81%
Century Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.56
Upside: +971.43%
Metagenomi
May 15, 2025
Maintains: Buy
Price Target: $13 → $12
Current: $1.58
Upside: +659.49%
May 13, 2025
Maintains: Buy
Price Target: $22 → $20
Current: $4.11
Upside: +387.21%
May 9, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $4.00
Upside: +525.00%
May 9, 2025
Maintains: Buy
Price Target: $30 → $25
Current: $1.73
Upside: +1,345.09%
May 9, 2025
Maintains: Buy
Price Target: $68
Current: $9.77
Upside: +596.01%
May 9, 2025
Maintains: Buy
Price Target: $9
Current: $0.65
Upside: +1,278.25%
May 7, 2025
Maintains: Buy
Price Target: $219
Current: $139.77
Upside: +56.69%
Apr 9, 2025
Initiates: Buy
Price Target: $50
Current: $22.14
Upside: +125.89%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.18
Upside: -
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.25
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $6.71
Upside: +511.48%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $5.55
Upside: +350.45%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.71
Upside: +601.75%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $27.33
Upside: +661.07%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.43
Upside: +1,018.88%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.99
Upside: +901.11%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $2.94
Upside: +36.05%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $2.47
Upside: +1,114.57%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $8.86
Upside: +103.27%